675112-40-0

Basic information

• Product Name: 4-AMINOCYCLOHEXANONE HCL
• Synonyms: 4-AMINOCYCLOHEXANONE HCL;4-AMINOCYCLOHEXANONE HYDROCHLORIDE;4-AMINOCYCLOHEXANE HYDROCHLORIDE;4-Aminocyclohexane HCl;Cyclohexanone, 4-aMino-, hydrochloride (1:1);4-AMinocyclohexan-1-one, HCl;4-aminocyclohexan-1-one,hydrochloride
• CAS NO: 675112-40-0
• Molecular Formula: C6H12ClNO
• Molecular Weight: 149.62
• Mol File: 675112-40-0.mol
• Article Data: 5

Chemical Properties

• Melting Point: 205 °C(dec.)
• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 4-AMINOCYCLOHEXANONE HCL(CAS DataBase Reference)
• NIST Chemistry Reference: 4-AMINOCYCLOHEXANONE HCL(675112-40-0)
• EPA Substance Registry System: 4-AMINOCYCLOHEXANONE HCL(675112-40-0)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Hazardous Substances Data: 675112-40-0(Hazardous Substances Data)

Usage

Chemical Properties

off-white powder

InChI:InChI=1/C6H11NO.ClH/c7-5-1-3-6(8)4-2-5;/h5H,1-4,7H2;1H

Upstream product

• 27514-08-5 N-(4-oxocyclohexyl)acetamide 
• 179321-49-4 N-(tert-butoxycarbonyl)-4-aminocyclohexanone 
• 204136-88-9 4-oxocyclohexane-1-carboxamide 
• 1431304-45-8 4,4-dimethoxycyclohexanecarboxamide 
• 17159-79-4 ethyl 4-oxocyclohexane-1-carboxylate 

Downstream Products

• 1610021-63-0 6-(benzo[d]thiazol-6-ylamino)-4-(isopropylamino)-N-(4-oxocyclohexyl)nicotinamide 

Relevant articles and documents

PYRAZOLOTRIAZOLOPYRIMIDINE DERIVATIVES AS A2A RECEPTOR ANTAGONIST

Disclosed herein is a pyrazolotriazolopyrimidine derivative or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof useful as an A2A receptor antagonist, and a pharmaceutical composition comprising the same. Also disclosed herein is a method of treating cancer using the pyrazolotriazolopyrimidine derivative or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof as an A2A receptor antagonist.

DIHYDROIMIDAZO [ 1, 5-F] PTERIDINES AS POLO-LIKE KINASE INHIBITORS

The present invention provides PLK inhibitors of the formula (I) wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using the compounds.

Novel thrombin inhibitors incorporating weakly basic heterobicyclic P1-arginine mimetics: optimization via modification of P1 and P3 moieties.

Optimization of lead compounds 1 and 2 resulted in novel, selective, and potent thrombin inhibitors incorporating weakly basic heterobicyclic P(1)-arginine mimetics. The design, synthesis, and biological activity of racemic thrombin inhibitors 17-29 and enantiomerically pure thrombin inhibitors 30-33 are described. The arginine side-chain mimetics used in this study are 4,5,6,7-tetrahydro-1,3-benzothiazol-2-amine, 4,5,6,7-tetrahydro-2H-indazole, and 2-imino-4,5,6,7-tetrahydro-1,3-benzothiazol-3(2H)-ylamine.